1 / 54

Supportive and Palliative Care in the Elderly

Supportive and Palliative Care in the Elderly. Roma, October 19, 2012. EMESIS. Sonia Fatigoni Medical Oncology Division, Terni. CINV. Are chemotherapy-induced nausea and vomiting (CINV) still a problem?. Intravenous agents Cisplatin

rob
Télécharger la présentation

Supportive and Palliative Care in the Elderly

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Supportive and Palliative Care in the Elderly Roma, October 19, 2012 EMESIS Sonia Fatigoni Medical Oncology Division, Terni

  2. CINV Are chemotherapy-induced nausea and vomiting (CINV) still a problem?

  3. Intravenous agents • Cisplatin • Mechlorethamine • Streptozocin • Cyclophosphamide >=1500 mg/m2 • Carmustine • Dacarbazine High emetic risk (>90%) • Oral agents • Hexamethylmelamina • Procarbazine

  4. Moderate emetic risk (30-90%) • Intravenous agents • Oxaliplatin • Citarabine > 1 g/m2 • Carboplatin • Ifosfamide • Cyclophosphamide<1500 mg/m2 • Doxorubicin • Daunorubicin • Epirubicin • Idarubicin • Irinotecan • Oral agents • Cyclophosphamide • Etoposide • Temozolomide • Vinorelbine • Imatinib

  5. CINV Over 50% of cancers occur in the 12% of the population aged 65 years or older • CINV can have important negative effects: • Quality of Life • Dehydration • Electrolyte disorders • Anorexia/malnutrition

  6. FEATURES OF NAUSEA AND VOMITINGASSOCIATED WITH CHEMOTHERAPY • ACUTE NAUSEA AND VOMITING • PERSISTENT OR DELAYED NAUSEA AND VOMITING • ANTICIPATORY NAUSEA AND VOMITING

  7. Centri superiori Memoria, emozioni S N C Centro del vomito Ipotalamo ipofisi cervelletto Nucleo del tratto solitario CTZ M1,D2, 5-HT3 P E R I F E R IA VAGO trigemino stomaco orecchio faringe cuore movimenti agenti emetogeni

  8. TREATMENT- AND PATIENT-RELATED VARIABLES • gender • age • history of ethanol consumption • history of emesis • anxiety • chemotherapy type • chemotherapy dose • infusion rate • route of administration • presence or absence of acute nausea and vomiting • nausea and vomiting in previous CT

  9. TREATMENT- AND PATIENT-RELATED VARIABLES Although the risk of experiencing of CINV generally decreased with advancing age, it is an expecially important complication in the elderly because these patients are more sensitive to the effects of cytotoxic cancer therapy The most important factor is the prevention of CINV

  10. Antiemetics • CORTICOSTEROIDS Dexametasone, Metilprednisolone • 5-HT3 RECEPTOR ANTAGONISTS Ondansetron, Granisetron, Tropisetron, Dolasetron, Palonosetron • DOPAMINE ANTAGONISTS Metoclopramide, Domperidone, Prochlorperazine, Aloperidol • NK-1 RECEPTOR ANTAGONISTS Aprepitant, Fosaprepitant The control of CINV is possible in about 80-90 % of patient, with the right combination of antiemetic drugs • OTHER Alprazolam

  11. LINEE GUIDA AIOM 2010 www.aiom.it Coordinatore: Roila F. Estensori: Caserta C, Fatigoni S. Revisori: Fabi A, Chiara S, Locatelli MC & Raffaele M.

  12. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia multinational Consensus ConferenceRoila F., et al. Ann Oncol 2010; 21(Suppl.5):228-39

  13. CASO CLINICO 1 Uomo di 75 anni con recente diagnosi di SCLC metastatico. Inizia una chemioterapia a base di cisplatino. Quale terapia antiemetica?

  14. 2009 PERUGIA CONSENSUS CONFERENCE To prevent acute vomiting and nausea following chemotherapy of high emetic risk, a three-drug regimen including single doses of a 5-HT3 antagonist, dexamethasone and aprepitant (or fosaprepitamt) given before chemotherapy is recommended MASCC: level of scientific confidence: high level of consensus: high ESMO, AIOM: level of evidence I grade of recommendation: A

  15. ADDITION OF THE NEUROKININ 1 RECEPTOR ANTAGONIST APREPITANT TO STANDARD ANTIEMETIC THERAPY IMPROVES CONTROL OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITINGPoli-Bigelli S. Cancer 2003; 97: 3090-8 THE ORAL NEUROKININ-1 ANTAGONIST APREPITANT FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING: A MULTINATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL IN PATIENTS RECEIVING HIGH-DOSE CISPLATIN Hesketh PJ. J Clin Oncol 2003; 21: 4112-19

  16. STUDY SCHEME: cisplatin-treated patients day 1 days 2-3 day 4 Aprepitant 125 mg 80 mg - Ondansetron 32 mg - - Desametasone 12 mg 8 mg 8 mg Ondansetron 32 mg - - Dexamethasone 20 mg 8 mg bid 8 mg bid Aprepitant p.o. Ondansetron i.v. Dexamethasone p.o. Poli-Bigelli S. Cancer 2003 Hesketh PJ. J Clin Oncol 2003

  17. RESULTS Protocol 052 Protocol 054 AOD OD AOD OD No. pts 264 266 283 286 Complete response (%) Day 1 89 78 83 68 Day 2-5 75 56 68 47 no nausea (%) 48 44 49 39 Poli-Bigelli S. Cancer 2003 Hesketh PJ. J Clin Oncol 2003

  18. SINGLE-DOSE FOSAPREPITANT FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING ASSOCIATED WITH CISPLATIN THERAPY: RANDOMIZED, DOUBLE-BLIND STUDY PROTOCOL-EASEGrunberg SM. J Clin Oncol 2011; 29: 1495-1501

  19. STUDY SCHEME: cisplatin-treated patients day 1 day 2-3 day 4 Aprepitantos 125 mg 80 mg - Ondansetron 32 mg - - Dexamethasone 12 mg 8 mg 8 mg day 1 day 2 days 3-4 Fosaprepitant iv 150 mg Ondansetron 32 mg - - Dexamethasone 12 mg 8 mg 8 mg bid Ondansetron i.v. Dexamethasone p.o. Grunberg SM, JCO 2011

  20. RESULTS FOD AOD p Day 1 89.0 88.0 n.s. Day 2-5 74.3 74.2 n.s. Day 1-5 71.9 72.3 n.s. Grunberg SM, JCO 2011

  21. DOSAGGI E SCHEDULE DEI 5HT3 ANTAGONISTI nell’ EMESI ACUTA indotta DA CISPLATINO

  22. 2009 PERUGIA CONSENSUS CONFERENCE In patients receiving cisplatin treated with a combination of aprepitant, a 5-HT3 antagonist and dexamethasone to prevent acute nausea and vomiting, the combination of dexamethasone and aprepitant is suggested to prevent delayed emesis, on the basis of its superiority to dexamethasone alone MASCC: level of scientific confidence: high level of consensus: moderate ESMO, AIOM: level of evidence: II grade of recommendation: A

  23. RISULTATI Protocol 052 Protocol 054 AOD OD AOD OD No. pts 264 266 283 286 Complete response (%) Day 1 89* 78 83* 68 Day 2-5 75* 56 68* 47 Day 1-5 73* 52 63* 43 no nausea (%) 48 44 49* 39 * Statisticamente significativo Hesketh PJ. J Clin Oncol 2003 Poli-Bigelli S. Cancer 2003

  24. EMESI RITARDATA DA CISPLATINO: UNO STUDIO DOPPIO-CIECO I.G.A.R. • 300 patienti hanno ricevuto una combinazione di aprepitant, palonosetron e desametasone per la prevenzione dell’emesi acuta da cisplatino • A partire dalla 24a ora dopo il cisplatino, sono stati randomizzati a ricevere: • - desametasone orale + metoclopramide • - desametasone orale + aprepitant

  25. CASO CLINICO 2 Donna di 70 anni operata di cr mammella. Inizia una chemioterapia adiuvante con epirubicina e ciclofosfamide. Quale terapia antiemetica?

  26. 2009 PERUGIA CONSENSUS CONFERENCE Women receiving a combination of anthracyclines plus cyclophosphamide represent a situation with a particular risk of vomiting and nausea. To prevent acute vomiting and nausea in these women, a three-drug regimen including single doses of a 5-HT3 antagonist, dexamethasone and aprepitant given before chemotherapy is recommended. MASCC: level of scientific confidence: high level of consensus: high ESMO: level of evidence I grade of recommendation: A

  27. EFFICACY AND TOLERABILITY OF APREPITANT FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN PATIENTS WITH BREAST CANCER AFTER MODERATELY EMETOGENIC CHEMOTHERAPY Warr D, et al. J Clin Oncol 2005; 23: 2822-30

  28. STUDY SCHEME: breast cancer pts treated with CTX ± DOX or EPI day 1 days 2-3 Aprepitant 125 mg 80 mg Ondansetron 8/8 mg - Desametasone 12 mg - Ondansetron 8/8 mg 8/8 mg Dexamethasone 20 mg - Aprepitant p.o. Ondansetron p.o. Dexamethasone p.o. Warr D, et al. J Clin Oncol, 2005

  29. RESULTS * AOD OD No. pts 438 428 p Day 1-5 51 42 0.015 Day 1 76 69 0.034 Day 2-5 55 49 0.064 No nausea days 1-5 33 33 n.s. *Complete response: no vomiting and no rescue therapy Warr D, et al. J Clin Oncol, 2005

  30. 2009 PERUGIA CONSENSUS CONFERENCE A combination of palonosetron plus dexamethasone is recommended for prophylaxis of acute nausea and vomiting in the first course of moderate risk emetogenic chemotherapy non A-C. MASCC: level of scientific confidence: moderate level of consensus: moderate ESMO: level of evidence II grade of recommendation: B

  31. PALONOSETRON IMPROVES PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING FOLLOWING MODERATELY EMETOGENIC CHEMOTHERAPY: RESULTS OF A DOUBLE-BLIND RANDOMIZED PHASE III TRIAL COMPARING SINGLE DOSES OF PALONOSETRON WITH ONDANSETRON Gralla RJ. Ann Oncol 2003; 14:1570-77 IMPROVED PREVENTION OF MODERATE CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING WITH PALONOSETRON, A PHARMACOLOGICALLY NOVEL 5-HT3 RECEPTOR ANTAGONIST: RESULTS OF A PHASE III SINGLE-DOSE TRIAL VERSUS DOLASETRON Eisemberg P. Cancer 2003; 98: 2473-82

  32. RISULTATI PAL PAL OND PAL PAL DOL Dose (mg)0.25 0.75 32 0.25 0.75 100 N° Pts192 190 188 201 197 194 Day 181.0* 73.5 68.6 63.0 57.1 52.9 Day 2-574.1* 64.6 55.1 54.0* 56.6* 38.7 Day 1-5 69.3* 58.7 50.3 46.0* 47.1* 34.0 * Statisticamente significativi Gralla RJ. Ann Oncol 2003 Eisemberg P. Cancer 2003

  33. PALONOSETRON PLUS DEXAMETHASONE VERSUS GRANISETRON PLUS DEXAMETASONE FOR PREVENTION OF NAUSEA AND VOMITING DURING CHEMOTHERAPY: A DOUBLE BLIND, DOUBLE-DUMMY, RANDOMIZED, COMPARATIVE PHASE III TRIAL. Saito M. Lancet Oncol 2009; 10: 115-24

  34. DISEGNO DELLO STUDIO day 1 days 2-3 Granisetron 40 mcg/kg --- Dexamethasone 16 mg iv 8 mg iv or 4 mg orally* Palonosetron 0.75 mg iv --- Dexamethasone 16 mg iv 8 mg iv or 4 mg orally* * In 1143 pts submitted to CDDP or M.E.C., respectively Saito M. Lancet Oncol 2009

  35. RISULTATI PD GD p Day 1 75.3 73.3 n.s. Day 2-5 56.8 44.5 0.0001 Day 1-5 51.5 40.4 0.0001

  36. 2009 PERUGIA CONSENSUS CONFERENCE If aprepitant is not available, palonosetron should be used with dexamethasone, in women receiving a combination of anthracyclines plus cyclophosphamide MASCC: level of scientific confidence: moderate level of consensus: moderate ESMO: level of evidence II grade of recommendation: B

  37. 2009 PERUGIA CONSENSUS CONFERENCE In patients receiving a combination of anthracyclines plus cyclophosphamide treated with a combination of aprepitant, a 5-HT3 receptor antagonist and dexamethasone to prevent acute nausea and vomiting, aprepitant or dexamethasone is suggested to prevent delayed emesis MASCC: level of scientific confidence: moderate level of consensus: moderate ESMO, AIOM: level of evidence II grade of recommendation: B

  38. RISULTATI AOD OD No. pts 438 428 p Day 1 76 69 0.034 Day 2-5 55 49 0.064 Days 1-5 51 42 0.01 No nausea days 1-5 33 33 n.s. Complete response: no vomiting and no rescue therapy Warr D, et al. J Clin Oncol, 2005

  39. EMESI RITARDATA INDOTTA DA MEC: UNO STUDIO DOPPIO-CIECO I.G.A.R. • 580 donne hanno ricevuto una combinazione di aprepitant, palonosetron e desametasone per la prevenzione dell’emesi acuta indotta da FEC, FAC, AC, EC. • A partire dalla 24a ora dopo la chemioterapia, le pazienti sono state randomizzate a ricevere: • - desametasone orale • - aprepitant

  40. 2009 PERUGIA CONSENSUS CONFERENCE Nei pazienti che ricevono una chemioterapia che non comprende la combinazione di antracicline e ciclofosfamide e per i quali è raccomandato il palonosetron, il trattamento da preferire per la prevenzione dell’emesi ritardata è costituito da desametasone orale per più giorni. Un 5-HT3 antagonista viene considerato come alternativa, nei casi in cui non possa essere usato lo steroide. MASCC: level of scientific confidence: moderate level of consensus: moderate ESMO, AIOM: level of evidence II grade of recommendation: B

  41. ANTIEMETICS FOR THE PREVENTION OF ACUTE EMESIS INDUCED BY LOW RISK EMETOGENIC CHEMOTHERAPY 2009 PERUGIA CONSENSUS CONFERENCE • A single agent (such as a low dose of a corticosteroid) is suggested for patients receiving agents of low emetic risk. • Level of scientific confidence: no confidence possible • Level of consensus: moderate

  42. Low emetic risk (10-30%) • Intravenous agents • Paclitaxel • Docetaxel • Mitoxantrone • Cytarabine<=100 mg/m2 • Topotecan • Etoposide • Pemetrexed • Methotrexate • Mitomycin • Gemcitabine • 5-Fluorouracil • Bortezomib • Cetuximab • Trastuzumab • Oral agents • Capecitabine • Fludarabine

  43. ANTIEMETICS FOR THE PREVENTION OF ACUTE EMESIS INDUCED BY MINIMAL RISK EMETOGENIC CHEMOTHERAPY 2009 PERUGIA CONSENSUS CONFERENCE • No antiemetic should be routinely administered before chemotherapy in patients without a history of nausea and vomiting. • Level of scientific confidence: no confidence possible • Level of consensus: high

  44. Minimal emetic risk (<10%) • Intravenous agents • Bleomycin • Busulfan • 2-Chlorodeoxyadenosine • Fludarabine • Vinblastine • Vincristine • Vinorelbine • Bevacizumab • Oral agents • Chlorambucil • Hydroxyurea • L-phenylamine mustard • 6-Tioguanina • Methotrexate • Gefitinib • Erlotinib

  45. ANTIEMETICS FOR THE PREVENTION OF DELAYED EMESIS INDUCED BY LOW AND MINIMAL RISK EMETOGENIC CHEMOTHERAPY 2009 PERUGIA CONSENSUS CONFERENCE • No antiemetic should be routinely administered for prophylaxis of delayed emesis in patients without a history of delayed nausea and vomiting. • Level of scientific confidence: no confidence possible • Level of consensus: high

  46. Studio prospettico osservazionale su 1148 pz (22.2% Spagna, 22.1% UK, 18.2 Italia, 13.6% Francia,9.1% Belgio,5.6% Svezia,5.3% Paesi Bassi, 4% Austria)

  47. Most elderly cancer patients have comorbid conditions that may interfere with their ability to tolerate antiemetic treatments: *diabetes * renal dysfunctions * hepatic dysfunctions ANTIEMETICS IN THE ELDERLY Polipharmacy is common in elderly cancer patients. This can interact with antiemetic drugs and can determine poor compliance with other oral drugs. * non-steroidal anti-inflammatory drugs * analgesics

  48. …about dexamethasone ANTIEMETICS IN THE ELDERLY The use of dexamethasone is not contra-indicated if not in presence of diabetic ketoacidosis and active peptic ulcer

  49. ANTIEMETICS IN THE ELDERLY …about 5-HT3 antagonists • It is not necessary to decrease the single dose of the 5-HT3 antagonist in patients with mild or moderate renal and hepatic dysfunction. • All 5-HT3 antagonists have similar efficacy and tolerability and can be used only as a single i.v. or oral dose in the first 24 hrs

More Related